trending Market Intelligence /marketintelligence/en/news-insights/trending/Sb9CIDHLT_MNne1v-RK0jg2 content esgSubNav
In This List

Valeant Pharmaceuticals prices, upsizes debt offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Valeant Pharmaceuticals prices, upsizes debt offering

Valeant Pharmaceuticals International Inc. priced its previously announced offering of 9.000% senior notes due 2025 at 98.611%.

The offering, which is expected to close by Dec. 18, was upsized to $1.5 billion from $1 billion.

Valeant plans to use net proceeds, along with cash on hand, to repurchase $1.5 billion of notes in a separate tender offer. It includes the company's outstanding 7.00% senior notes, 6.375% senior notes and 5.375% senior notes, all due 2020.

The notes will be guaranteed by each of Valeant's subsidiaries that are guarantors under the company's credit agreement and its existing senior notes.

Completion of the offering is subject to various closing conditions.